| Predicted Trait | |
| Reported Trait | Breast cancer |
| Mapped Trait(s) | breast carcinoma (EFO_0000305) |
| Score Construction | |
| PGS Name | PRS3820_BC |
| Development Method | |
| Name | LASSO penalized regression |
| Parameters | p < 0.001 |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 3,820 |
| Effect Weight Type | NR |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000002 |
| Citation (link to publication) | Mavaddat N et al. Am J Hum Genet (2018) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 158,648 individuals (100%) |
| Score Development/Training | European: 100% 10,444 individuals (100%) |
| PGS Evaluation | |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
| — | [ ,
0.0 % Male samples |
European | 68 cohorts
|
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) | Phenotype Definitions & Methods | Age of Study Participants | Participant Follow-up Time | Additional Ancestry Description | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| — | [ ,
0.0 % Male samples |
European | 25 cohorts
|
Invasive breast cancer-affected | — | — | — | Validation Cohort |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM000008 | PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Invasive breast cancer | OR: 1.66 [1.61, 1.7] | AUROC: 0.636 | — | study, genetic PCs 1-15 | — |
| PPM000386 | PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | — | AUROC: 0.78 | — | age, sex | — |
| PPM000384 | PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | OR: 1.56 [1.45, 1.68] | — | — | age at menarche | — |
| PPM000388 | PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | — | AUROC: 0.63 | — | — | — |
| PPM005169 | PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.59 [0.58, 0.6] | R²: 0.021 | — | — |
| PPM005172 | PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.53 [0.5, 0.57] | R²: 0.0002 | — | — |
| PPM005160 | PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.36 [1.31, 1.41] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM005163 | PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.21 [1.06, 1.39] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
| PPM015517 | PSS009971| Multi-ancestry (including European)| 36,422 individuals |
PGP000381 | Hao L et al. Nat Med (2022) |Ext. |
Reported Trait: Breast cancer | OR: 2.38 [2.07, 2.73] | — | — | 4 genetic PCs | — |
| PPM023068 | PSS012107| European Ancestry| 4,805 individuals |
PGP000767 | Beck JJ et al. Cancers (Basel) (2024) |Ext. |
Reported Trait: Breast cancer | β: 0.029 (0.004) | AUROC: 0.603 | R²: 0.153 | age, 10 PCs | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS003598 | Cases were individuals with breast cancer. Breast cancer cases were defined by at least one occurrence of the following ICD10CM female breast cancer diagnostic codes: C50.01, C50.011, C50.012, C50.019, C50.1, C50.11, C50.111, C50.112, C50.119, C50.2, C50.21, C50.211, C50.212, C50.219, C50.3, C50.31, C50.311, C50.312, C50.319, C50.4, C50.41, C50.411, C50.412, C50.419, C50.5, C50.51, C50.511, C50.512, C50.519, C50.6, C50.61, C50.611, C50.612, C50.619, C50.81, C50.811, C50.812, C50.819, C50.91, C50.911, C50.912, C50.919, D05, D05.1, D05.10, D05.11, D05.12, D05.8, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92, Z85.3,Z86.000 and ICD9CM female breast cancer diagnostic codes: 174, 174, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233, V10.3. Alternatively breast cancer cases were defined by at least two occurrences (from distinct calendar days) of breast cancer history from the following ICD10CM codes: Z85.3, Z86.000 and ICD9CM code: V10.3, if she had no breast cancer diagnostic codes. | — | [ ,
0.0 % Male samples |
Mean = 59.6 years Sd = 16.5 years |
African unspecified | — | eMERGE | — |
| PSS003599 | Cases were individuals with breast cancer. Breast cancer cases were defined by at least one occurrence of the following ICD10CM female breast cancer diagnostic codes: C50.01, C50.011, C50.012, C50.019, C50.1, C50.11, C50.111, C50.112, C50.119, C50.2, C50.21, C50.211, C50.212, C50.219, C50.3, C50.31, C50.311, C50.312, C50.319, C50.4, C50.41, C50.411, C50.412, C50.419, C50.5, C50.51, C50.511, C50.512, C50.519, C50.6, C50.61, C50.611, C50.612, C50.619, C50.81, C50.811, C50.812, C50.819, C50.91, C50.911, C50.912, C50.919, D05, D05.1, D05.10, D05.11, D05.12, D05.8, D05.81, D05.82, D05.9, D05.90, D05.91, D05.92, Z85.3,Z86.000 and ICD9CM female breast cancer diagnostic codes: 174, 174, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 233, V10.3. Alternatively breast cancer cases were defined by at least two occurrences (from distinct calendar days) of breast cancer history from the following ICD10CM codes: Z85.3, Z86.000 and ICD9CM code: V10.3, if she had no breast cancer diagnostic codes. | — | [ ,
0.0 % Male samples |
Mean = 66.1 years Sd = 17.7 years |
European | — | eMERGE | — |
| PSS009971 | — | — | 786 individuals | — | Asian unspecified | — | MGBB | — |
| PSS012107 | — | — | 4,805 individuals, 0.0 % Male samples |
— | European | — | BCCR, NTR, iCaRe2 | — |
| PSS000218 | Phenotypic information was self-reported by the individual through an online, interactive health history tool | — | [ ,
0.0 % Male samples |
— | European | — | CG | Samples are individuals whose healthcare provider had ordered a Color Genomics multi-gene panel test |
| PSS009971 | — | — | 1,807 individuals | — | African unspecified (Black) |
— | MGBB | — |
| PSS000004 | Invasive breast cancer-affected | — | [ ,
0.0 % Male samples |
— | European | — | 10 cohorts
|
Prospective Test Set |
| PSS009971 | — | — | 3,113 individuals | — | Other | — | MGBB | — |
| PSS009971 | — | — | 30,716 individuals | — | European | — | MGBB | — |